Our Company
About CuraCell
CuraCell is a European biotech company developing T-cell therapies to treat cancer. Our proprietary T-cell expansion and activation platform, CytoPLY, disrupts the development of curable treatment options for some of the most deadly solid cancer tumors.
Based on leading researchers and clinicians from Sweden and Germany we are committed to bring durable life-saving treatments to patients diagnosed with terminal cancer.
Contact usLarge Impact Potential for Cancer Patients Worldwide
Every cancer is different. Even if the same organ is affected, tumor cells can express different markers, called antigens. CuraCell develops personalized medicine, amplifying the patient’s tumor-reactive cells.
Solid cancers accounts for ~90% of all cancers. TIL therapy is a potential durable therapy that could target a wide range of solid cancers. CuraCell strives to make significant impact for cancer patients worldwide.
Management
Advisory Board
